Thetford Mines, June 1st, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) is proud to announce an agreement with ZoomMed Inc. (TSXV: ZMD) (“ZoomMed”) whereby KDA Group can distribute under a non-exclusive license the ZRx Prescriber developed by ZoomMed in the United States.
- KDA Group has signed a letter of intent for the acquisition of CONSUTLANDGROW
- KDA Group annouces definitive closing of private placement
- KDA Group annouces the appointment of Dr Giuseppe D’Aprano as Chief Scientific Officer
- KDA Group completes previously announced sales of a majority stake in Pharmapar
- KDA Group signed a share purchase agreement with Strides for the sales of majority stake in Pharmapar